Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 0.83% | 9.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.83% | 9.95% | |||
| Cost of Revenue | -0.69% | 7.96% | |||
| Gross Profit | 2.17% | 11.76% | |||
| SG&A Expenses | 1.70% | -0.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.10% | 3.68% | |||
| Operating Income | 6.59% | 111.63% | |||
| Income Before Tax | -0.63% | 178.59% | |||
| Income Tax Expenses | -53.08% | 204.92% | |||
| Earnings from Continuing Operations | 23.48% | 170.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.48% | 170.46% | |||
| EBIT | 6.59% | 111.63% | |||
| EBITDA | 4.30% | 51.26% | |||
| EPS Basic | 23.32% | 171.02% | |||
| Normalized Basic EPS | -7.51% | 84.01% | |||
| EPS Diluted | 22.89% | 170.83% | |||
| Normalized Diluted EPS | -7.85% | 83.55% | |||
| Average Basic Shares Outstanding | 0.13% | -0.79% | |||
| Average Diluted Shares Outstanding | 0.49% | -0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||